Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.53 +3.0%	$6.71	$5.81 ▼ $14.38	$618.54M	0.83	397,066 shs	457,627 shs
CATX Perspective Therapeutics	$3.81 -4.3%	$3.74	$1.60 ▼ $16.55	$282.81M	1.17	953,450 shs	1.81 million shs
HSAQ Health Sciences Acquisitions Co. 2	$2.72 +7.9%	$3.01	$9.41 ▼ $13.80	$30.50M	0.09	205,918 shs	527,865 shs
SWAV Shockwave Medical	$334.75	$332.85	$157.00 ▼ $334.90	$12.57B	0.88	968,088 shs	N/A

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+5.48%	+19.06%	+4.88%	+14.58%	-3.31%
CATX Perspective Therapeutics	+6.99%	+1.53%	0.00%	+84.26%	-67.08%
HSAQ Health Sciences Acquisitions Co. 2	0.00%	+1.12%	-7.19%	-7.82%	-55.65%
SWAV Shockwave Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	2.9685 of 5 stars	3.4	0.0	0.0	0.0	1.8	3.3	1.3
CATX Perspective Therapeutics	1.598 of 5 stars	3.6	1.0	0.0	0.0	2.4	0.8	0.0
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	82.60% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	229.54% Upside
HSAQ Health Sciences Acquisitions Co. 2	0.00	N/A	N/A	N/A
SWAV Shockwave Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SWAV, BVS, CATX, and HSAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00
5/14/2025	CATX Perspective Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
5/13/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.10	$0.60 per share	12.58	$2.80 per share	2.69
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
SWAV Shockwave Medical	$787.97M	15.95	$4.31 per share	77.61	$20.02 per share	16.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	16.37	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	8/13/2025 (Estimated)
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	0.00	∞	N/A	N/A	N/A	-2.38%	N/A
SWAV Shockwave Medical	$147.28M	$4.28	78.21	54.34	2.43	20.75%	24.79%	11.95%	N/A

Latest SWAV, BVS, CATX, and HSAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	N/A	CATX Perspective Therapeutics	-$0.30	-$0.30	N/A	N/A	$0.17 million	$0.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
SWAV Shockwave Medical	0.97	13.81	12.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
HSAQ Health Sciences Acquisitions Co. 2	89.71%
SWAV Shockwave Medical	95.35%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.52%
HSAQ Health Sciences Acquisitions Co. 2	21.90%
SWAV Shockwave Medical	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.23 million	65.21 million	Optionable
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
SWAV Shockwave Medical	1,468	37.54 million	36.27 million	Optionable

SWAV, BVS, CATX, and HSAQ Headlines

Recent News About These Companies

Navigating Shockwave Medical: Applicant Admitted Prior Art, Standing, and Obviousness

August 4, 2025 | jdsupra.com

Shockwave Medical unveil Forward Intravascular Lithotripsy Platform in US

March 6, 2025 | medicaldialogues.inM

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

March 4, 2025 | finance.yahoo.com

Shockwave Medical’s Javelin IVL catheter meets primary trial endpoints

November 5, 2024 | massdevice.com

Shockwave Medical concludes enrollment in all-female coronary IVL study

November 2, 2024 | medicaldialogues.inM

Shockwave completes enrollment in all-female cardiovascular trial

October 30, 2024 | bioworld.comB

Shockwave Medical completes enrollment in all-female IVL study

October 29, 2024 | massdevice.com

Micro-shockwave electronic therapy shows potential for safe non-invasive treatment of brain disorders

October 28, 2024 | medicalxpress.comM

Mayo Clinic Q&A: Shockwave therapy may help relieve foot problem

October 27, 2024 | postbulletin.comP

Johnson & Johnson completes $1.7B V-Wave acquisition

October 9, 2024 | massdevice.com

New shockwave therapy offers hope for chronic pain sufferers

September 25, 2024 | local12.comL

Shockwave E8: Extend Your Capabilities With the New Peripheral IVL Workhorse

September 24, 2024 | evtoday.comE

Shockwave E8 Peripheral IVL Catheter Launched

September 17, 2024 | evtoday.comE

Smiths Medical recalls airway tubes over defect linked to more than 10 injuries

September 17, 2024 | medtechdive.comM

J&J’s Shockwave adds enhanced catheter to U.S. IVL portfolio

September 17, 2024 | massdevice.com

J&J’s Shockwave strengths IVL grasp with new US catheter launch

September 17, 2024 | msn.com

New noninvasive technique provides effective treatment for urinary stones

September 12, 2024 | msn.com

Balancing Growth and Challenges: A Hold Rating for Johnson & Johnson’s Medtech Division Amidst China Headwinds

September 6, 2024 | markets.businessinsider.com

September 2024 edition: The Medtech Big 100, PFA catheters and Shockwave’s Reducer

August 30, 2024 | medicaldesignandoutsourcing.comM

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

August 22, 2024 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SWAV, BVS, CATX, and HSAQ Company Descriptions

Bioventus NYSE:BVS

$7.53 +0.22 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$7.40 -0.13 (-1.66%)

As of 07:14 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$3.81 -0.17 (-4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 +0.06 (+1.71%)

As of 07:56 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$2.72 +0.20 (+7.94%)

As of 08/12/2025

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time